Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, B-Cell × Cisplatin × Clear all

Phase

Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 133 Lung Neoplasms 53 Nasopharyngeal Carcinoma 49 Uterine Cervical Neoplasms 47 Squamous Cell Carcinoma of Head and Neck 42 Head and Neck Neoplasms 42 Parkinson Disease 4, Autosomal Dominant Lewy Body 31 Stomach Neoplasms 30 Esophageal Neoplasms 28 Urinary Bladder Neoplasms 21 Small Cell Lung Carcinoma 20 Esophageal Squamous Cell Carcinoma 20 Ovarian Neoplasms 13 Carcinoma 12 Recurrence 11 Neoplasm Metastasis 11 Neuroblastoma 10 Cholangiocarcinoma 10 Biliary Tract Neoplasms 10 Gallbladder Neoplasms 9 Adenocarcinoma Of Esophagus 9 Testicular Neoplasms 8 Nasopharyngeal Neoplasms 8 Carcinoma, Transitional Cell 8 Carcinoma, Ovarian Epithelial 8 Teratoma 7 Endometrial Neoplasms 7 Central Nervous System Neoplasms 7 Carcinoma, Squamous Cell 7 Oropharyngeal Neoplasms 6

Interventions

Rituximab 12 pirtobrutinib 5 ibrutinib 4 Vincristine 3 Doxorubicin 3 Cytarabine 3 zanubrutinib 2 Prednisone 2 Etoposide 2 Cyclophosphamide 2 Bendamustine Hydrochloride 2 venetoclax 1 tositumomab I-131 1 idelalisib 1 ibritumomab tiuxetan 1 etoposide phosphate 1 entecavir 1 cirmtuzumab 1 axicabtagene ciloleucel 1 acalabrutinib 1 VAP-cyclo protocol 1 Tenofovir 1 Radiotherapy 1 Methotrexate 1 Melphalan 1 Ifosfamide 1 Gemcitabine 1 Drug Therapy 1 Dexamethasone 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06230224 2026-02-06

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡